Fig 1.
A decision tree comparing the new screening test strategy with the current screening test in UK, The Netherlands, Ireland, and Sweden.
UK: United Kingdom.
Table 1.
Input parameters.
Table 2.
Estimated costs (Euro, 2020).
Table 3.
Cost-effectiveness of new test strategy versus current screening strategy in exploratory scenario analyses in four participating countries, i.e. UK, The Netherlands, Ireland and Sweden.
Fig 2.
Cost-effectiveness planes of the new screening test for preeclampsia versus current screening strategy in base-case scenario analyses in four participating countries.
UK: United Kingdom, NL: The Netherlands, IR: Ireland, SW: Sweden, PE: preeclampsia.
Fig 3.
Cost-effectiveness acceptability curves for the new screening test in best-case scenario analyses in a different willingness to pay thresholds ranging from €10,000 - €100,000 per preeclampsia cases averted, in four participating countries.
UK: United Kingdom, NL: The Netherlands, IR: Ireland, SW: Sweden.